

Ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

HealthTech guidance
Published: 24 July 2019

www.nice.org.uk/guidance/htg523

Your responsibility

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account, and specifically any special arrangements relating to the introduction of new interventional procedures. The guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the [Yellow Card Scheme](#).

Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. Providers should ensure that governance structures are in place to review, authorise and monitor the introduction of new devices and procedures.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should [assess and reduce the environmental impact of implementing NICE recommendations wherever possible](#).

Contents

1 Recommendations	4
2 The condition, current treatments and procedure.....	6
The condition.....	6
Current treatments.....	6
The procedure	6
3 Committee considerations	8
The evidence	8
Committee comments.....	8
Update information	9

This guidance replaces IPG657.

1 Recommendations

- 1.1 Current evidence on the safety of ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids shows there are well-recognised complications including skin burns. The evidence on efficacy is limited in quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. [Find out what special arrangements mean on the NICE guidance page](#).
- 1.2 Clinicians wishing to do ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids should:
 - Inform the clinical governance leads in their NHS trusts.
 - Ensure that patients understand the procedure's safety and efficacy, as well as any uncertainties about these and provide them with clear written information to support [shared decision making](#). In addition, the use of [NICE's information for the public](#) is recommended.
 - Audit and review clinical outcomes of all patients having ultrasound-guided high intensity transcutaneous focused ultrasound for symptomatic uterine fibroids. [NICE has identified relevant audit criteria and has developed an audit tool](#) (which is for use at local discretion).
- 1.3 During the consent process clinicians should tell patients that their symptoms may not be fully relieved and may return, and that further procedures may be needed. They should also tell patients about the risk of skin burns. Patients considering pregnancy should be told that the effects of the procedure on fertility and future pregnancy are uncertain.
- 1.4 Patient selection should be done by a multidisciplinary team including a gynaecologist and an appropriate imaging specialist.
- 1.5 The procedure should only be done in specialised centres by clinicians with

specific training in this technique.

- 1.6 NICE encourages further research and prospective data collection. Studies comparing ultrasound-guided high-intensity focused ultrasound with other therapies such as uterine artery embolisation and MRI-guided high-intensity transcutaneous focused ultrasound would be useful. Studies should report patient selection (including size, location and number of fibroids), patient-reported outcome measures, long-term outcomes and subsequent pregnancy rates.

2 The condition, current treatments and procedure

The condition

- 2.1 Uterine fibroids are benign tumours of the uterine wall. They can be asymptomatic or cause symptoms including menorrhagia, intermenstrual bleeding, pelvic pressure or pain, and urinary incontinence. They can be associated with fertility problems and miscarriage.

Current treatments

- 2.2 Treatment depends on whether the fibroids cause symptoms, and if the person would like to have children in the future. For symptomatic fibroids, treatment options include medications, interventional radiology and surgery. Interventional radiology treatments include uterine artery embolisation and MRI-guided focused ultrasound. Surgery includes hysterectomy, myomectomy, endometrial ablation techniques and myolysis.

The procedure

- 2.3 Ultrasound-guided high-intensity transcutaneous focused ultrasound (HIFU) for symptomatic uterine fibroids is done with the patient lying face down, with the abdominal wall immersed in degassed water. Intravenous sedation may be used to help minimise body movement. A urinary catheter is inserted to keep the bladder empty during the procedure. Continuous sonographic imaging is used to identify the fibroid(s) with a real-time diagnostic ultrasound scanner integrated into the centre of a therapeutic ultrasound transducer. After the target fibroid has been confirmed, it is ablated by high-intensity ultrasound energy. The patient may have to lie still for up to 3 hours.

- 2.4 Ultrasound-guided HIFU uses grayscale or echogenicity changes to determine the adequacy of ablation. After treatment, imaging (by ultrasound or MRI scan) is used to evaluate the volume of the fibroid ablated.

3 Committee considerations

The evidence

- 3.1 To inform the committee, NICE did a rapid review of the published literature on the efficacy and safety of this procedure. This comprised a comprehensive literature search and detailed review of the evidence from 9 sources, which was discussed by the committee. The evidence included 1 randomised controlled trial, 4 non-randomised comparative studies, 3 case series and 1 case report, and is presented in [table 2 of the overview](#). Other relevant literature is in the appendix of the overview.
- 3.2 The specialist advisers and the committee considered the key efficacy outcomes to be: patient-reported outcome measures, quality of life, fibroid size, subsequent pregnancy rates and need for further intervention.
- 3.3 The specialist advisers and the committee considered the key safety outcomes to be: pain, skin burns, vaginal discharge and bleeding, and damage to adjacent structures (including bowel injury).
- 3.4 [One commentary from a patient who had experience of this procedure was received](#), which was discussed by the committee.

Committee comments

- 3.5 Most evidence reviewed by the committee came from studies done outside the UK and there was some uncertainty about the generalisability of this evidence to the UK setting.
- 3.6 There may be additional safety concerns in patients who have had previous abdominal surgery (including caesarean section); in patients who are obese; and in patients who have a retroverted uterus.

Update information

Minor changes since publication

January 2026: Interventional procedures guidance 657 has been migrated to HealthTech guidance 523. The recommendations and accompanying content remain unchanged.

ISBN: 978-1-4731-7982-0

Endorsing organisation

This guidance has been endorsed by Healthcare Improvement Scotland.